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SUMMARY
The present communication illustrates the results of a computational study based on molecular 
topology, focused on the repositioning of drugs to treat the SARS-CoV-2 virus, better known as 
coronavirus, responsible for the COVID-19 disease. Using lopinavir, a well-known viral protease 
inhibitor as the reference drug, a mathematical pattern is found allowing the screening of the market 
drugs, searching for potential candidates to inhibit the said enzyme. This way new possible therapeu-
tic alternatives to fight the coronavirus are found.
Results indicate that antivirals such as brecanavir, as well as various groups of drugs, among which 
are antibiotics of the macrolide family (azithromycin, clarithromycin and erythromycin among oth-
ers) could be useful in treating COVID-19 infection.
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RESULTS AND DISCUSSION
The Molecular Topology and Drug Design Research Unit from the University of Valencia (Spain) 
has been working in a pioneering way since the 1980s in designing and selecting new drugs based 
on a paradigm called Molecular Topology (MT). Some of these new drugs have been internationally 
patented in fields as diverse as cancer, Alzheimer’s and malaria [1].
In essence, the MT method consists in characterizing the molecules by a set of numbers, called 
topological indices, which basically depend on the structure of each molecule and therefore on its 
pharmacological activity. In this way, it is possible to group the molecules into sets that respond to 
different mathematical patterns according to their activity. For example, we can have the anticancer 
pattern, even the anticancer pattern associated with a specific mechanism (for example, topoisomer-
ase inhibitors).
Once a mathematical pattern has been found, it is easy to ask the computer to search for new mol-
ecules matching the same pattern and therefore showing the same pharmacological activity, but with 
better pharmacodynamic, pharmacokinetic, or toxicological properties (more potency, better absorp-
tion, less toxicity, etc.). By using a mathematical pattern to characterize pharmacological activity, the 
authors are able to identify a great structural variability within the potential active compounds.
Given the current pandemic situation, now that the structure of the virus protease has been pub-
lished [2] and that some antivirals inhibiting proteases have been published as slightly effective 
against the virus, the authors in this communication disclose the results of a topological screening of 
the market drugs, selecting those which may present significant anti-COVID-19 activity.
One of them, which we have taken as the gold-standard or reference drug, is lopinavir, which ac-
cording to various publications seems to have shown effectiveness against SARS-CoV-2.
After obtaining their topological-mathematical fingerprint through seven predictive equations (not 
reflected here), the authors proceeded to screen two databases of pharmacological compounds: Com-
prehensive Medicinal Chemistry [3] and DrugBank [4], altogether some 15,000 molecules.
Table 1. Results obtained from the virtual screening of selected drugs as potential protease inhibitors 
and therefore useful in the treatment of COVID-19
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Drug Family Inhibitory capability to SARS- CoV-2 protease
Cethromycin Antibiotic 5,7










Cistinexine Expectorant and Mucolytic 3,6
Cefbuperazone Antibiotic 3,2
Lopinavir Antiviral 2,9
The right column indicates the range of inhibitory potency against protease of the different drugs 
with an index (in arbitrary units). The reference drug lopinavir appears in bold at the bottom and 
showed a value of 2.9 on this scale.
As can be seen, there is a surprisingly high number of drugs that show theoretical activity against 
the virus protease, including known antivirals, antibiotics of different types and other groups of drugs 
(antineoplastic, antiallergic, etc.).
Among the most active are brecanavir (potency index 7.3) and an ionophore antibiotic, nonactin 
(index 10, the maximum). It is also noteworthy that there are some antibiotics from the macrolide 
family, such as clarithromycin and erythromycin. Another potentially useful drug is murabutide, since 
it is a known immunostimulant, which could promote a synergy.
Obviously, only experimental confirmation of the activity in vitro and in vivo of these compounds 
against the virus will demonstrate their real efficacy. However, the repositioning of drugs can shorten 
significantly the time in providing therapeutic alternatives to deal with the current public health crisis. 
In this sense, the authors believe that the drugs reported in Table 1 represent an important contribu-
tion, whose fast achievement is another proof of MT’s power as a tool for the search of new drugs.
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